{"id":"placebo-atazanavir","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1200678","moleculeType":"Small molecule","molecularWeight":"802.95"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Placebo Atazanavir contains no active drug substance and produces no direct molecular or therapeutic effect. It is used as a control comparator in clinical trials to assess the efficacy and safety of active atazanavir treatment by comparison against an inert formulation.","oneSentence":"This is a placebo formulation with no active pharmacological mechanism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:15.806Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in phase 3 clinical trials for HIV infection"}]},"trialDetails":[{"nctId":"NCT04468087","phase":"PHASE2, PHASE3","title":"Antiviral Agents Against COVID-19 Infection","status":"COMPLETED","sponsor":"Hospital do Coracao","startDate":"2021-02-15","conditions":"COVID-19","enrollment":256},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT01803074","phase":"PHASE2","title":"Study to Evaluate a HIV Drug for the Treatment of HIV Infection","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2013-04-04","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":107},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT01705574","phase":"PHASE3","title":"Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-10-24","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":583},{"nctId":"NCT01967940","phase":"PHASE3","title":"Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-10-25","conditions":"HIV, HIV Infections, Acquired Immunodeficiency Syndrome","enrollment":55},{"nctId":"NCT00118898","phase":"PHASE3","title":"Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2005-09","conditions":"HIV Infections","enrollment":1864},{"nctId":"NCT02556268","phase":"PHASE1","title":"Interaction With HIV Antiretroviral Agents","status":"COMPLETED","sponsor":"Bayer","startDate":"2016-02-23","conditions":"HIV-DDI","enrollment":40},{"nctId":"NCT00720590","phase":"NA","title":"Effect of the HIV Protease Inhibitors Atazanavir and Lopinavir/Ritonavir on Cardiovascular Disease Risk Factors","status":"COMPLETED","sponsor":"Indiana University","startDate":"2003-11","conditions":"Endothelial Dysfunction","enrollment":30},{"nctId":"NCT03019783","phase":"PHASE2, PHASE3","title":"Atazanavir and Endothelial Function in Older HIV Patients","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2011-12","conditions":"HIV","enrollment":60},{"nctId":"NCT02442700","phase":"PHASE4","title":"Effects of Pitavastatin on Lipid Profiles in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir","status":"COMPLETED","sponsor":"Ramathibodi Hospital","startDate":"2014-05","conditions":"HIV, Dyslipidemia","enrollment":24},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":724},{"nctId":"NCT01108510","phase":"PHASE3","title":"Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-04","conditions":"HIV, HIV Infections","enrollment":698},{"nctId":"NCT00892437","phase":"PHASE2","title":"Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2009-05","conditions":"HIV-1 Infection","enrollment":85},{"nctId":"NCT01106586","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-04","conditions":"HIV, HIV Infections","enrollment":708},{"nctId":"NCT00916448","phase":"NA","title":"The Effects of Atazanavir-induced Hyperbilirubinemia During Human Endotoxemia","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2009-05","conditions":"Endotoxemia, Inflammation, Multi Organ Dysfunction Syndrome","enrollment":30},{"nctId":"NCT00013897","phase":"PHASE3","title":"A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2001-02","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00696722","phase":"PHASE2","title":"Effects of Atazanavir Treatment on Type 2 Diabetes Mellitus Related Endothelial Dysfunction","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2008-06","conditions":"Type 2 Diabetes Mellitus Related Endothelial Dysfunction","enrollment":16}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo group","Reyataz","BMS-232632"],"phase":"phase_3","status":"active","brandName":"Placebo Atazanavir","genericName":"Placebo Atazanavir","companyName":"Hospital do Coracao","companyId":"hospital-do-coracao","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo formulation with no active pharmacological mechanism. Used for Control arm in phase 3 clinical trials for HIV infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}